治疗前HBeAg水平与HBeAg水平早期下降预测恩替卡韦治疗HBeAg阳

StephenW

                          治疗前HBeAg水平与HBeAg水平早期下降预测恩替卡韦治疗HBeAg阳性慢性乙肝的病毒应答
                          Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg‐positive chronic hepatitis B                   

                           来自:J VIRAL HEPATITIS(2012-02-01)

                              

              作者：                               J. H. Kwon, J. W. Jang, S. Lee, J. Lee, K. W. Chung, Y. S. Lee, J. Y. Choi                           
                PMID：                                                           暂无                                                                          

                   There are few reports on hepatitis B e antigen (HBeAg) titres during nucleos(t)ide analogues treatment. We investigated the changes in HBeAg levels in patients treated with entecavir and the usefulness of HBeAg quantification for predicting antiviral response. Ninety-five consecutive HBeAg-positive patients treated with entecavir for more than 48 weeks were enrolled. Serum levels of hepatitis B surface antigen (HBsAg), HBeAg and HBV DNA were assessed at 4-week intervals to week 24 and thereafter at 12-week intervals. Virologic response (Y1VR) was defined as an undetectable HBV DNA level at week 48 of therapy. During 48 weeks, HBeAg and HBV DNA level decreased significantly in a biphasic manner and HBsAg level tended to decease. Fifty-three patients (55.8%) attained Y1VR. Pretreatment HBeAg levels were significantly lower in the Y1VR group than in no Y1VR group. At week 4 and 12 of therapy, 25% and 41.4% of patients showed a decrease of HBeAg levels with >0.5 log10 and >1.0 log10 from baseline, respectively. These patients achieved more Y1VR than those with less decrease of HBeAg levels (97.7%vs 22.2% and 86.2%vs 29.3%, respectively). HBeAg level at week 12 had higher predictive values for Y1VR than HBV DNA level. Multivariate analysis revealed that a pretreatment HBeAg level of <360 PEIU/mL and the reduction in HBeAg level >1.0 log10 at week 12 were associated with Y1VR. These results suggest that pretreatment HBeAg level and an early decrease in HBeAg level are useful measurements for predicting one-year virologic response during entecavir treatment.            

StephenW

HBeAg的水平，早在HBeAg水平下降的预处理预测恩替卡韦治疗HBeAg阳性慢性乙型肝炎的病毒学应答

来自：J病毒性肝炎（2012年2月1日）有15次阅读分享（0）

JH权JW张，李学​​，J.李涌千瓦，YS李，JY财
关键词：暂无
核苷（酸）IDE类似物治疗期间有B型肝炎e抗原（HBeAg）滴度的报道很少。我们调查的恩替卡韦治疗的患者和HBeAg的量化预测抗病毒反应的效用在HBeAg水平的变化。九十五年连续超过48周与恩替卡韦治疗HBeAg阳性患者参加。乙肝表面抗原（HBsAg）血清在4周的时间间隔24周，HBeAg和HBV DNA进行了评估，其后在12个星期的时间间隔。病毒学应答（Y1VR）被定义为检测不到乙肝病毒DNA水平在治疗48周。在48周时，HBeAg和HBV DNA水平显着下降双相方式和HBsAg水平往往到减幅。五十三例（55.8％）达到Y1VR。预处理HBeAg的水平显着低于在Y1VR组没有Y1VR组。周4和12治疗，25％和41.4％的患者> 0.5> 1.0 log10和LOG10，分别从基线减少HBeAg的水平。这些患者取得Y1VR多与少的HBeAg水平下降（97.7％比22.2％和86.2％比29.3％，分别）。 12周时HBeAg的水平为Y1VR HBV DNA水平高于预测值。多元统计分析表明，预处理HBeAg的水平<360 PEIU /毫升，在HBeAg水平下降> 1.0 log10的12周与Y1VR关联。这些结果表明，预处理HBeAg的水平，并在年初减少HBeAg的水平是有用的测量，预测一年恩替卡韦治疗期间病毒学应答。